Tag Archives: Pharmacological Research

European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)

Posted on February 3, 2016 by Dementia and Elderly Care News

Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →

Big Data Portal for Alzheimer’s Dementia Drug Discovery (NIH / Synapse AMP-AD)

Posted on March 8, 2015 by Dementia and Elderly Care News

Summary The National Institutes of Health (NIH) in the USA has opened a public-private partnership online resource to facilitate neurodegenerative research and drug development. The launch of the Alzheimer’s Big Data Portal provides an open-source “public knowledge portal” for the … Continue reading →

Posted in Charitable Bodies, For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights | Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Accelerating Alzheimer's Research and Drug Development, Accelerating Medicine Partnership for Alzheimer's Disease (NIA-AMP AD) Target Discovery and Preclinical Validation Project, Accelerating Medicines Partnership (AMP), Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD), Alfred P. Sloan Foundation, Alzheimer’s Disease Biomarkers, Alzheimer’s Disease Cooperative Study, Alzheimer’s Disease Neuroimaging Initiative (ADNI), AMP-AD Program, Big Data, Big Data Portal for Alzheimer’s Dementia Drug Discovery, Big Pharma, Biomarkers, Biopharmaceutical Companies, Broad Institute of MIT and Harvard, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Cross-Sector Partnerships, Dementia Research, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Emory University, Foundation for the NIH (FNIH), Genetic Research, Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Global Open Data Initiative, Human Epigenome Atlas, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology (Seattle), International Alzheimer's Disease Research Portfolio (IADRP), International Collaborations, International Organisations, International Programmes, Market Failure (Dementia Research and Drug Development), Mayo Clinic in Jacksonville, Medical Research, Multidisciplinary Research Teams, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NIA Genetics of Alzheimer’s Data Storage Site (NIAGADS), NIH Big Data to Knowledge (BD2K) Initiative, NIH Network for Excellence in Neuroscience Clinical Trials, Non-Profit Collaborations, Novel Targets in Neurodegeneration, Open Data, Open Data and Big Data, Open Data in Health and Social Care, Open Data Learning Capacity and Culture, Open Data: Unlocking Innovation, Open Source Solutions, Pharmaceutical Industry, Pharmacological Research, Potential of Open Data in Health and Social Care, Pre-Competitive Collaboration, Precision Medicine Initiative, Preclinical Biomarkers in Alzheimer's Disease, Public-Private Partnership (PPP), Public-Private Partnerships, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Roadmap Epigenomics Project, Rush University Medical Center: Chicago, Sage Bionetworks, Synapse, Synapse Access and Compliance Team, Target Discovery and Preclinical Validation, Technology Transfer, Temporal Evolution of Alzheimer’s Disease Biomarkers, Therapeutic Target(s): Identification, Translational Research, Transparency and Open Data, United States, University of California, University of Florida, US National Institute of Aging, US National Institutes of Health (NIH), USA | Leave a comment

UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)

Posted on February 16, 2015 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK has announced the launch of the Drug Discovery Alliance, a £30 million network of research centres working collaboratively on research to discover potential cures, or at least disease modifying treatments, for Alzheimer’s Disease and other forms … Continue reading →

Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)

Posted on December 22, 2014 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK has launched the Global Clinical Trials Fund (GCTF) to help finance trials which aim to translate discoveries in the lab into clinical treatments for the 830,000 people living with dementia in the UK. The GCTF aims … Continue reading →

Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged Alzheimer’s Research UK Drug Discovery Institute, Clinical Research Networks, Clinical Trials, Clinical Trials (Phase I Through Phase III), Clinical Trials and Treatment Assessments, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Commissioning Research, Dementia Consortium, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, GCTF: Global Clinical Trials Fund, Global Action Against Dementia, Global Clinical Trials Fund (GCTF), International Collaborations, International Organisations, International Programmes, Intervention Trials, Medical Research, Multidisciplinary Research Teams, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Non-Drug Intervention Trials, Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Research Commitment, Research Consortia, Research Culture, Research Programmes, Technology Transfer, Translational Research | Leave a comment

Second Global Dementia Legacy Event: Ottawa, September 11th/12th 2014 (Department of Health / Dementia Challenge / World Dementia Council / CIHR / AVIESAN)

Posted on September 11, 2014 by Dementia and Elderly Care News

Summary Canada and France are co-hosting the second Global Action Against Dementia Legacy Event in Ottawa (Canada) on September 11th – 12th 2014. This event will explore how to take advantage of partnership working and collaboration between industry and academia, … Continue reading →

Posted in Acute Hospitals, Community Care, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Universal Interest | Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Academic-Industry Collaborations, Alain Beaudet: President of Canadian Institutes of Health Research (CIHR), Alice Wong: Minister of State (Seniors) in Canada, Alzheimer Society of Canada, AVIESAN: French National Alliance for Life Sciences and Health, •Alzheimer Society of Canada, Big Data, Biotechnology, Canada, Canada's Research Strategy for Alzheimer's Disease, Canada-France Legacy Event, Canadian Institutes of Health Research (CIHR), Challenge on Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia in Canada, Dementia Innovation, Dementia Research, Dementia Time-Bomb, Dennis Gillings: Former World Dementia Envoy, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug-Development Pipeline, Faye Forbes (Living With Dementia), France, Free Open Access Journals, G7 Global Dementia Summit, G8 Dementia Summit, G8 Dementia Summit Agreements, G8 Summit on Dementia Communique, G8 Summit on Dementia Declaration, Global Action Against Dementia, Global Context, Global Dementia Legacy Event, Global Dementia Legacy Event on Academia-Industry Synergies, Global Leadership, Global Outlook, Incentives and Investment, Incentives for Drug Development, Innovation, Innovative Medicines Initiative, Institute of Health and Medical Research (Inserm), International Collaborations, International Programmes, Japan Legacy Event, Knowledge Networks, Knowledge Translation, Massachusetts Biotech Cluster: CONNECT, Matthew Dineen (Carer), Medical Devices, Networks, Networks and Alliances, Neurological Research, OECD Big Data and Sustainability Initiative for Large-Scale Research on Dementia, Open Access, Open Access Databases, Open Access Journals, Open Access Knowledge Resources, Open Access Research, Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmaceutical Industry, Pharmacological Research, Philippe Zeller: Ambassador of France to Canada, Prime Minister's Challenge on Dementia, Prime Minister’s Dementia Challenge, Regulatory Barriers: Regulatory Environment, Removing Regulatory Barriers, Research and Innovation, Research Networks, Resource and Incentives, Second Global Dementia Legacy Event, Second Global Dementia Legacy Event (Ottawa: September 2014), The Honourable Rona Ambrose: Minister of Health (Canada), UK Legacy Event, USA Legacy Event, Venture Capital (Approach to Research), World Dementia Council, Yves Lévy: French National Institute of Health and Medical Research (Inserm) and Chairman of Aviesan (French National Alliance for Life Sciences and Health Care) | Leave a comment

Google’s “Moonshot Project” on Tackling Ageing (Financial Times / Reuters / BBC News / ICO / Health and Technology)

Posted on September 5, 2014 by Dementia and Elderly Care News

Summary Arthur Levinson, formerly of Genentech, has left Roche to avoid any potential conflict of interest in his role as chief executive of Google’s Calico start-up company. Calico recently agreed a $1.5bn alliance with AbbVie, a rival of Roche, to develop treatments for … Continue reading →

Posted in Assistive Technology, In the News, International, Management of Condition, Non-Pharmacological Treatments, Parkinson's Disease, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged 23andMe, AbbVie, Acute Kidney Injury (AKI), Age and Ageing, Age-Related Disease Research, Age-Related Neurodegenerative and Neurovascular Diseases, Ageing and Dementia, Ageing and Society, Ageing Population, Ageing Well, Arthur Levinson, Attitudes to Ageing, Basline Study: Collection of Anonymous Genetic and Molecular Information, BBC Health News, Big Data, Big Pharma, Compensation for Shaky Hands (Assistive Technology), Data Protection Act (1998), Data Protection Procurement Rules and Competition Rules (Potential Barriers to Information Sharing), Data Protection Procurement Rules and Competition Rules (Potential Barriers to Partnership Working), Data Sharing, Data Sharing Agreement, Data Sharing for Better Health, Diffusion of Innovation, Disease-Detecting Nanoparticles, Economist (Journal), Elizabeth Denham, Elizabeth Denham: Information Commissioner, Encouraging Innovation, Essential Tremor, Faculty of Law and Computer Laboratory: University of Cambridge, Financial Times, FT.com, Genentech, Google, Google Ageing-Related Ambitions, Google Basline Study: Anonymous Genetic and Molecular Information, Google Health-Related Ambitions, Google Moonshot Projects, Google Moonshot Projects: Ageing-Related, Google X, Google X: Cutting-Edge Technology Projects, Google X: Potentially Revolutionary Innovation, Google's DeepMind, Google's Research Division: Google X, Google's Social Network: Google+, Google’s Calico, Google’s DeepMind and Royal Free Trust Data-Sharing Agreement, Google’s Health Portfolio, Health and Technology (Journal), Health Technology, Healthy Life Expectancy, Human Longevity, Information Commissioner’s Office (ICO), Information Commissioner’s Website, International Collaborations, International Dementia Research Inventories, International Programmes, International Research, Lift Labs, Longevity, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Data and Big Data, Open Science, Open Source Solutions, Partnership and Collaboration, Partnership Working, Pharmaceutical Industry, Pharmacological Research, Policies on Ageing, Preventative Care, Proactive Care, Reinventing Ageing, Research and Innovation, Reuters, Roche, Royal Free Hospital (London), Royal Free London NHS Trust, Royal Free NHS Foundation Trust, Science of Ageing, Smart Contact Lenses, Stabilization Technology: Tremor Cancellation, Streams app (Google’s DeepMind), Supporting Healthy Lifestyles, Tremor, Tremor and Other Hyperkinetic Movements, Tremor Cancellation Spoon (Stabilization Technology), Tremor-Cancelling Devices | Leave a comment

Dementia Consortium (Alzheimer’s Research UK)

Posted on July 15, 2014 by Dementia and Elderly Care News

Summary The Dementia Consortium has been established to fund academic dementia research experts from the UK and overseas in their efforts to develop early research findings concerning Alzheimer’s Disease, and other forms of dementia, into validated drug targets. “The Dementia … Continue reading →

Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, UK | Tagged ARUK: Alzheimer’s Research UK, Big Pharma, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Dementia Consortium, Dementia Research, Dementia Research Priorities, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Eisai Ltd, Eli Lilly, Fast-Tracking New Potential Treatments, Justin Bryans: MRC Technology, Lilly, MRC Technology, MRC Technology (Independent Life Science Technology Transfer Charity), MRCT: MRC Technology, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Technology Transfer, Translational Research | Leave a comment

Tag Archives: Pharmacological Research

European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)

UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)

Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)

Second Global Dementia Legacy Event: Ottawa, September 11th/12th 2014 (Department of Health / Dementia Challenge / World Dementia Council / CIHR / AVIESAN)

Dementia Consortium (Alzheimer’s Research UK)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites